Literature DB >> 11975694

Laxative prescribing in relation to opioid use and the influence of pharmacy-based intervention.

M L Bouvy1, H Buurma, T C G Egberts.   

Abstract

INTRODUCTION: Opioid-induced constipation is a common problem and can cause serious complications. It is widely advised that laxatives should be started concurrently with opiates, unless there is a clear indication not to do so.
OBJECTIVE: This study was undertaken to estimate how often laxatives were started concurrently with opiates and to describe the effect of pharmacy-based interventions to promote the use of laxatives in patients starting opioids.
METHODS: Twenty-six community pharmacies identified all patients who received a first prescription for a strong opioid during January and February of 1998, 1999 or 2000. Pharmacists collected information on patient, drug and prescriber characteristics (age, gender, use of opiates and laxatives). A separate questionnaire was used to collect data on pharmacy-based interventions to promote the simultaneous prescribing of laxatives with the opiates.
RESULTS: Overall, 37% of the patients receiving an opioid started taking laxatives within 5 days. The percentage of patients who received laxatives simultaneously with opioids increased from 31% in 1998 to 35% in 1999 and 42% in 2000. In 117 (43%) of the opioid prescriptions, pharmacy-based intervention had taken place before the prescription date. Of these, 48.7% was accompanied by a laxative. Opioid prescriptions (n=152) without a pharmacy based intervention were accompanied in 27.6%. After adjustment for covariates (including time trends), pharmacy-based intervention increased the probability of concomitant laxative use 1.9 [95% CI 1.1-3.3] times. DISCUSSION: This study shows that the widely used guideline to start a laxative when prescribing an opioid is not always followed in daily practice. In addition, we showed that pharmacy-based intervention contributed to increasing laxative use in patients receiving opioids.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11975694     DOI: 10.1046/j.1365-2710.2002.00385.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  7 in total

1.  Evaluation of the clinical value of pharmacists' modifications of prescription errors.

Authors:  Henk Buurma; Peter A G M De Smet; Hubert G M Leufkens; Antoine C G Egberts
Journal:  Br J Clin Pharmacol       Date:  2004-11       Impact factor: 4.335

2.  Clinical risk management in Dutch community pharmacies: the case of drug-drug interactions.

Authors:  Henk Buurma; Peter A G M De Smet; Antoine C G Egberts
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 3.  A composite screening tool for medication reviews of outpatients: general issues with specific examples.

Authors:  Peter A G M De Smet; Wilma Denneboom; Cees Kramers; Richard Grol
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

4.  The use of opioids at the end of life: the knowledge level of Dutch physicians as a potential barrier to effective pain management.

Authors:  Mette L Rurup; Christiaan A Rhodius; Sander D Borgsteede; Manon Sa Boddaert; Astrid Gm Keijser; H Roeline W Pasman; Bregje D Onwuteaka-Philipsen
Journal:  BMC Palliat Care       Date:  2010-11-12       Impact factor: 3.234

5.  Preventive medication use among persons with limited life expectancy.

Authors:  André R Maddison; Judith Fisher; Grace Johnston
Journal:  Prog Palliat Care       Date:  2011-01

6.  Pharmacotherapeutic management of chronic noncancer pain in primary care: lessons for pharmacists.

Authors:  Ghaya Jouini; Manon Choinière; Elisabeth Martin; Sylvie Perreault; Djamal Berbiche; David Lussier; Eveline Hudon; Lyne Lalonde
Journal:  J Pain Res       Date:  2014-03-24       Impact factor: 3.133

7.  Laxative co-medication and changes in defecation patterns during opioid use.

Authors:  Frans de Bruin; Karin Hek; Jan van Lieshout; Monique Verduijn; Pim Langendijk; Marcel Bouvy; Martina Teichert
Journal:  J Oncol Pharm Pract       Date:  2018-09-27       Impact factor: 1.809

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.